BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33854094)

  • 21. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
    Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
    Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
    Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
    Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
    Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
    J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular spectrum of
    Al-Shamsi HO; Jones J; Fahmawi Y; Dahbour I; Tabash A; Abdel-Wahab R; Abousamra AO; Shaw KR; Xiao L; Hassan MM; Kipp BR; Kopetz S; Soliman AS; McWilliams RR; Wolff RA
    J Gastrointest Oncol; 2016 Dec; 7(6):882-902. PubMed ID: 28078112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
    Kim H; Kim BH; Lee D; Shin E
    Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.
    Jauhri M; Bhatnagar A; Gupta S; Shokeen Y; Minhas S; Aggarwal S
    Med Oncol; 2016 Oct; 33(10):106. PubMed ID: 27568332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy.
    Nakamura M; Kageyama SI; Seki M; Suzuki A; Okumura M; Hojo H; Motegi A; Akimoto T
    Anticancer Res; 2021 Feb; 41(2):829-834. PubMed ID: 33517288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
    Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
    Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation analysis of 13 driver genes of colorectal cancer-related pathways in Taiwanese patients.
    Chang YC; Chang JG; Liu TC; Lin CY; Yang SF; Ho CM; Chen WT; Chang YS
    World J Gastroenterol; 2016 Feb; 22(7):2314-25. PubMed ID: 26900293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience.
    Youssef ASE; Abdel-Fattah MA; Lotfy MM; Nassar A; Abouelhoda M; Touny AO; Hassan ZK; Mohey Eldin M; Bahnassy AA; Khaled H; Zekri ARN
    Curr Issues Mol Biol; 2022 Mar; 44(3):1332-1352. PubMed ID: 35723313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.